vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
1. VTVT secures $80 million in PIPE financing for cadisegliatin development. 2. CATT1 Phase 3 trial data expected in late 2026. 3. Funding supports advanced glycemic control in type 1 diabetes patients. 4. Cadisegliatin is under FDA Breakthrough Therapy designation. 5. New and existing investors participate in financing round.